UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 9, 2024

TELA Bio, Inc.

(Exact name of registrant as specified in its charter)

001-39130 (Commission

File Number)

(State or other jurisdiction of incorporation)

Delaware

1 Great Valley Parkway, Suite 24 Malvern, Pennsylvania (Address of principal executive offices)

Registrant's telephone number, including area code: (484) 320-2930

Not Applicable (Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company 🗵

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. \Box

45-5320061 (I.R.S. Employer Identification No.)

Name of each exchange on which registered Nasdaq Global Market

19355 (Zip Code)

<u>Trading Symbol(s)</u> TELA

<u>Title of each class</u> Common Stock, par value \$0.001 per share

Item 2.02 Results of Operations and Financial Condition.

On May 9, 2024, TELA Bio, Inc. (the "Company") issued a press release announcing its financial results for the first quarter ended March 31, 2024. A copy of this press release is furnished as Exhibit 99.1 hereto.

The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "*Exchange Act*"), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended (the "*Securities Act*"), or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 7.01 Regulation FD Disclosure.

On May 9, 2024, the Company updated information reflected in a corporate slide deck, which representatives of the Company will use in various meetings with investors from time to time. A copy of the presentation is attached hereto as Exhibit 99.2, and incorporated herein by reference.

The information furnished pursuant to Item 7.01, including Exhibit 99.2, shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

The following exhibits are being furnished herewith:

Exhibit No.	Document
	Press Release of TELA Bio, Inc., dated May 9, 2024.
<u>99.2</u>	Corporate Slide Deck, dated May 9, 2024.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TELA BIO, INC.

By: Name: Title:

/s/ Antony Koblish Antony Koblish President, Chief Executive Officer and Director

Date: May 9, 2024

CE. VALUE. INNOVATION

TELA Bio Reports First Quarter 2024 Financial Results

MALVERN, PA, May 9, 2024 -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions today reported financial results for the first quarter ended March 31, 2024.

Recent Highlights

- Reported revenue of \$16.6 million in the first quarter, representing growth of 39% over the prior year period of 2023;
- Delivered the 13th consecutive quarter of at least 35% year-over-year growth; Increased demand for OviTex® and OviTex PRS Reinforced Tissue Matrix products during the first quarter, resulting in a year-over-year revenue increase for each product of approximately 31% and 54%, respectively;
- Appointed Howard N. Langstein, MD, FACS, as Vice President of Medical Affairs and Surgeon Strategy; Commenced full U.S. commercial launch of Robotic-Compatible OviTex IHR (Inguinal Hernia Repair) Reinforced Tissue Matrix, specifically for use in laparoscopic and robotic-assisted inguinal hernia repairs; and Increased full year 2024 revenue guidance to \$74.5 million to \$76.5 million, representing 27% to 31% year-over-year growth.

"We've begun 2024 with strong momentum led by a maturing sales force, strategic product portfolio launches, and sustained market share growth across our OviTex portfolio," said Antony Koblish, co-founder, President, and Chief Executive Officer of TELA Bio. "TELA Bio is focused on optimizing this growth phase, driving our sales force towards a more balanced selling approach across the Hernia and PRS franchises, generating increasing operating leverage over time, and continuing to deliver value to surgeons and patients. Q1 was a strong quarter and we believe the rest of 2024 will continue to showcase the progress TELA is delivering on key strategic priorities."

First Quarter 2024 Financial Results

Revenue was \$16.6 million in the first quarter of 2024, an increase of 39% compared to the same period in 2023. The increase was due to an increase in unit sales of our products and the continued expansion of the commercial organization, which resulted in increased penetration of existing customer accounts, the addition of new customers, and growing international sales.

Gross profit was \$11.3 million in the first quarter of 2024, or 68% of revenue, compared to \$7.9 million, or 66% of revenue, in the same period in 2023. The increase in gross margin was primarily due to a lower charge for excess and obsolete inventory as a percentage of revenue due to improvements in inventory management

Operating expenses were \$23.7 million in the first quarter of 2024, compared to \$19.2 million in the same period in 2023. The increase was due to higher compensation costs and employee-related expenses from additional headcount as we continue to expand our organization, as well as increased travel, consulting, and higher costs for research and development activities.

Loss from operations was \$4.8 million in the first quarter of 2024, compared to a loss from operations of \$11.3 million in the same period in 2023. The decrease was driven primarily by the recognition of a one-time gain of \$7.6 million from the sale of certain assets related to the NIVIS Fibrillar Collagen Pack Device ("NIVIS") to MiMedx in March 2024, subject to adjustment in future periods as we reassess our estimate of variable consideration from the transaction.

Net loss was \$5.7 million in the first quarter of 2024, compared to a net loss of \$12.0 million in the same period in 2023.

Conference Call

TELA Bio will host a conference call at 4:30 p.m. Eastern Time on Thursday, May 9, 2024 to discuss its first quarter 2024 financial results. Investors interested in listening to the conference call should register online. Participants are required to register a day in advance or at minimum 15 minutes before the start of the call. A live webcast and replay can be accessed via the Events & Presentations page of the investor section of TELA's website.

About TELA Bio, Inc.

TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. For more information, visit <u>www.telabio.com</u>.

Caution Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements and reflect the current beliefs of TELA Bio's management. Such forward-looking statements include statements relating to our expected revenue and revenue growth for the full year 2024. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements including, among others: the impact to our business from macroeconomic conditions, including any lingering effects of the COVID-19 pandemic and other public health crises, recessionary concerns, banking instability, increasing market interest rates, and inflationary pressures, potentially impacting our ability to market our products, demand for our products due to the deferral of elective procedures, the labor and staffing environment in the healthcare industry, disruption in our supply chain, or pricing pressures concerning our products or the procedures using our products and interim data from ongoing studies may not be replicated in later studies or indicative of outcomes in other surgical settings; our ability to enhance our product small profiles inducting problems; capacity constraints or delays in productis; maintenance of coverage and adequate reimbursement for procedures using our products; maintenance of reviews, and total estimates are described more fully in the "Risk Factors" section and elsewhere in our filings with the Securities and Exchange Commission and available at www.sec.gov, including in our Annual Report on Form 10-K and Quartery Reports on Form 10-Q. A

Investor Contact Louisa Smith ir@telabio.com

TELA Bio, Inc. Consolidated Balance Sheets (In thousands, except share and per share amounts) (Unaudited)

	March 31, 2024		December 31, 2023	
Assets		2024		2025
Current assets:				
Cash and cash equivalents	\$	37,143	\$	46,729
Accounts receivable, net of allowances of \$303 and \$416		9,955		9,737
Inventory		13,602		13,162
Prepaid expenses and other assets		1,918		2,098
Total current assets		62,618		71,726
Property and equipment, net		2,325		1,984
Intangible assets, net		2,024		2,119
Right-of-use assets		1,904		1,954
Other long-term assets		2,701		_
Restricted cash		265		265
Total assets	\$	71,837	\$	78,048
Liabilities and stockholders' equity				
Accounts pavable	\$	3,357	\$	1,667
Accrued expenses and other current liabilities	Ψ	11,822	Ψ	15,300
Total current liabilities		15,179		16,967
Long-term debt		40,665		40,515
Other long-term liabilities		1,609		1,685
Total liabilities		57,453		59.167
i utal naunites		57,455		59,107
Stockholders' equity:				
Preferred stock; \$0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding		_		_
Common stock; \$0.001 par value: 200,000,000 shares authorized; 24,653,939 and 24,494,675 shares issued and outstanding at March 31, 2024 and December 31, 2023,				
respectively		25		24
Additional paid-in capital		340,812		339,655
Accumulated other comprehensive income		97		91
Accumulated deficit		(326,550)		(320,889)
Total stockholders' equity		14,384		18,881
Total liabilities and stockholders' equity	\$	71,837	\$	78,048

TELA Bio, Inc. Consolidated Statements of Operations and Comprehensive Loss (In thousands, except share and per share amounts) (Unaudited)

	Three months ended March 31,		
	2024		2023
Revenue	\$ 16,603	\$	11,909
Cost of revenue (excluding amortization of intangible assets)	5,172		3,916
Amortization of intangible assets	95		95
Gross profit	11,336		7,898
Operating expenses:			
Sales and marketing	17,520		13,466
General and administrative	3,829		3,634
Research and development	2,393		2,052
Total operating expenses	23,742		19,152
Other operating income:			
Gain on sale of product line	(7,580)		—
Loss from operations	(4,826)		(11,254)
Other expense:			
Interest expense	(1,332)		(1,246)
Other income	497		473
Total other expense	(835)		(773)
Net loss	\$ (5,661)	\$	(12,027)
Net loss per common share, basic and diluted	\$ (0.23)	\$	(0.63)
Weighted average common shares outstanding, basic and diluted	 24,579,386		19,185,621
Comprehensive loss:			
Net loss	\$ (5,661)	\$	(12,027)
Foreign currency translation adjustment	6		(30)
Comprehensive loss	\$ (5,655)	\$	(12,057)





INVESTOR PRESENTATION

May 2024

Forward Looking Statements

This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this document, including but not limited to statements regarding possible or assumed future results of operations, business strategies, development plans, regulatory activities, market opportunity competitive position, potential growth opportunities, and the effects of competition, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause TELA Bio, Inc.'s (the "Company") actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project, "contemplate," "believe," "estimate," "protential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this presentation are only predictions. The Company has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that it believes may affect the Company's business, financial condition and results of operations. These forward-looking statements speak only as of the date of this presentation and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond the Company's control, including, among others: the impact to the Company's business from macroeconomic conditions, including any lingering effects of the COVID-19 pandemic or other public health crises, recessionary concerns, banking instability, increasing market interest rates, and inflationary pressures, potentially impacting our ability to market our products, demand for our products due to the deferral of elective procedures, the labor and staffing environment in the healthcare industry, disruption in our supply chain, or pricing pressures concerning our products or the procedures using our products; our ability to achieve or sustain profitability; the Company's ability to gain market acceptance for the Company's products and to accurately forecast and meet customer demand; the Company's ability to compete successfully; that data from earlier studies related to the Company's products and interim data from ongoing studies may not be replicated in later studies or indicative of future data, that data obtained from clinical studies utilizing the Company's products may not be indicative of outcomes in other surgical settings; the Company's ability to enhance the Company's product offerings; development and manufacturing problems; capacity constraints or delays in production of the Company's products; maintenance of coverage and adequate reimbursement for procedures using the Company's products; product defects or failures. These and other risks and uncertainties are described more fully in the "Risk Factors" section and elsewhere in the Company's filings with the Securities and Exchange Commission and available at www.sec.gov. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in the Company's forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, the Company operates in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that the Company may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise



TELA Bio, Inc.

- Advanced reinforced tissue matrix portfolio supported by compelling clinical evidence
- \$2.2B US market opportunity¹ still in early stages of growth
- Driving commercial adoption with targeted direct-sales
 approach
- Recent product launches in growing markets: robotic hernia surgery, plastic and reconstructive surgery
- · Broad intellectual property portfolio
- Established DRG-based reimbursement pathway for hernia repair and robust GPO access
- · Highly accomplished executive team with proven track record

Redefining soft tissue preservation and restoration with a differentiated category of tissue reinforcement materials and supportive products





¹ Management estimate. \$2.2B total includes \$1.5B hernia & abdominal wall reconstruction, \$0.7B plastic reconstructive surgery.



U.S. Hernia Surgery Market: ~\$1.5 Billion Annual Opportunity



¹Sources: Millennium Research Group Reports, IMS Health Data; iData Research MedSKU ²Management estimate. Market size based on volume and weighted average selling price for OviTex



OviTex Reinforced Tissue Matrix

A More Natural Hernia Repair®

OviTex Core

4-layer device No smooth sides Robot Compatible¹: Yes

OviTex Core is designed to reinforce primary hernia repairs where the device will not come into contact with viscera.

OviTex 1S

6-layer device 1 smooth side Robot Compatible¹: Yes

OviTex 1S incorporates a smooth side that is designed to minimize tissue attachment and to reinforce primary hernia repairs where the device may come into contact with viscera (e.g. intraperitoneal).

OviTex 2S

8-layer device 2 smooth sides Robot Compatible: No

OviTex 2S incorporates eight layers of tissue for added strength. The two smooth sides make it suitable for intraperitoneal placement.

OviTex LPR

4-layer device 1 smooth side Robot Compatible¹: Yes

OviTex LPR is designed specifically for use in minimally invasive procedures. The design also incorporates a smooth side making it suitable for intraperitoneal placement.

OviTex IHR

4-layer and 3-layer device No smooth sides Robot Compatible²: Yes

OviTex IHR is designed specifically for use in inguinal hernia repair procedures. The design also incorporates an anatomical and rectangular shape to suit surgeon preference.

1, Robot compatibility based on use of 10mm trocar. Robot compatibility of LPR and OviTex Core include sizes 400 cm² or less. Robot compatibility of OviTex 1S includes sizes 200 cm² or less 2. Robot compatibility based on use of 8mm trocar. Robot compatibility of OviTex IHR include sizes of 221 cm² or less.

Need for Alternative to Permanent Synthetic Mesh

59%	of surgeons agree that use of permanent synthetic mesh puts patients at long-term risk of complications ¹					
3 of 4	Hernia patients want proactive control in their care ²					
~24,000	Lawsuits against permanent synthetic meshes estimated to be assembled across the U.S. ³					

TELABIO[®]


SCIENCE, VALUE, INNOVATION.

Hernia and Abdominal Surgeries Survey (Oct 2020). A group of 71 surgeons were surveyed regarding use of mesh in various hernia repair surgeries.
 Figures derived from Company-sponsored poll of approximately 1,100 potential patients for hernia procedures.
 <u>www.drugwatch.com</u> (September 2022)

Consistently Low Recurrence Rates

Backed by 7+ years of clinical experience and 35+ published or presented works





Source: Refer to "Ovitex Clinical References" in this presentation. * Indicates one or more surgeons are paid consultants of Tela Bio, Inc.

Favorable Results of OviTex in Ventral Hernia Repair: Comparisons to synthetic mesh and leading generation one biologics

	Park	er et al. ⁸	Sivaraj et al. ⁵			
Total enrolled patients	50 OviTex	50 Polypropylene	36 OviTex	51 Strattice	17 Permacol	37 Surgimend
Length of follow-up	12 months	12 months	28.6 months (median)	34.6 months (median)	58.4 months (median)	37.5 months (median)
mVHWG	32% grade 2 68% grade 3ª	94% grade 2 6% grade 3	33% grade 1 58% grade 2 8% grade 3	17% grade 1 79% grade 2 4% grade 3	18% grade 1 71% grade 2 12% grade 3	40% grade 1 51% grade 2 9% grade 3
CDC wound class	70% CDC class II+ ª	94% CDC class I	89% class I-II	86% class I-II	94% class I-II	91% class I-II
Incidence of SSO	36%*	22%*	16.7%*	47.1%*	52.9%*	43.2%*
Incidence of SSI	-	÷	2.8% ^b	12.5%	11.8%	5.4%
Recurrence rate	6%	12%	2.8% ℃	13.7% ^c	29.4%	24.3%

*Overall complications including SSI

a – OviTex patients were more complicated with a significantly higher mVHWG distribution and CDC wound classification compared to polypropylene patients
 b – OviTex patients experienced significantly less complications than patients receiving the other three biologics
 c – OviTex and Strattice patients had a statistically lower recurrence rate than patients receiving the other two biologics

Source: Refer to "Clinical References" in this presentation.



Positive 24-month BRAVO results in ventral hernia: OviTex performance contextualized alongside recent publications for leading competitive products

	DeNoto et al. (BRAVO) ⁷	Harris et al	I. (PRICE) ¹⁰	Roth et al. ¹¹	Hope et al. (ATLAS) ¹²
Total enrolled patients	92 OviTex	82 Strattice	83 Ventralight ST or Bard Soft Mesh	121 Phasix	120 Phasix ST
Length of follow-up	24 months	26 months		36 months	24 months
mVHWG	78% grade 2-3	-		-	-
CDC wound class	95% class I-II	90% class I-II	93% class I-II	100% class I	100% class I
Surgical technique	Open (65%) Laparoscopic (13%) Robotic (22%)	Open	Open	Open	Laparoscopic (55.8%) Robotic (44.2%)
Incidence of SSO	38% (includes SSI)	21% (excludes SSI)	22% (excludes SSI)	-	0.8% (includes SSI)
Incidence of SSI	20.7%	39%	34%	9%*	0%
Recurrence rate	2.6%*	40% (overall) 34% (class I wounds)	22% (overall) 28% (class I wounds)	17.9%*	31.7%* (overall) 18.6%* (defects < 7cm²)

* Kaplan-Meier survival estimate


Kapian-Meler Survival estimate **No head-to-head clinical studies have been conducted. Due to differences in patient population, surgeons, surgical technique, and other variables, no direct comparisons of results can be made. For a comparative discussion of these studies, please see G. DeNoto, E.P. Ceppa, S.J. Pacella, M. Sawyer, G. Slayden, M. Takata, G. Tuma, J. Yunis, 24-Month results of the BRAVO study: A prospective, multi-center study evaluating the clinical outcomes of a ventral hemia cohort treated with OviTex® 1S permanent reinforced tissue matrix, Ann Medicine Surg 2022, 83, 104745.



Source: Refer to "Clinical References" in this presentation.

Hernia Market Evolution

TELA Bio is gaining from a market shift by providing our reinforced "natural repair" solutions as an alternative to traditional Permanent Synthetics or Biologics





U.S. Plastic and Reconstructive Surgery Market: ~\$700 Million Annual Opportunity



Surgeons use products to reinforce soft tissue during various reconstructive surgeries¹, including:

- Head and neck surgery
- Chest wall reconstruction
- Pelvic reconstruction
- Extremities reconstruction
- Breast reconstruction

Market dominated by human acellular dermal matrices (HADMs):

- Prone to high degree of stretch
- Expensive, putting pressure on hospital systems
- ^a Can experience supply shortages, particularly when large pieces of material are required

¹OviTex PRS is for implantation to reinforce soft tissue where weakness exists in patients requiring soft tissue repair or reinforcement in plastic and reconstructive surgery. The device is supplied sterile and is intended for one-time use. OviTex PRS has not been tested in breast surgical procedures. ²Management estimate. Source: iData Research MedSKU, Q3 2021. Market size based on sales of current biologics







OviTex PRS: Specifically Designed for Plastic and Reconstructive Surgery

Available in both 2-layer resorbable (polyglycolic acid) polymer, 3-layer permanent (polypropylene) polymer, or 3layer resorbable (polylactic-co-glycolic acid) polymer reinforcing the same biologic material



An innovative reinforced tissue matrix designed to improve outcomes by facilitating fluid management and controlling degree and direction of stretch

Product Features:

- Layers composed of biologic building block retain biologically significant macromolecules for tissue regeneration^{1,2}
- Diamond embroidery pattern and stents allow for directional flexibility; sawtooth embroidery pattern and slits allow for bidirectional stretch while providing stretch resistance.
- Distinct permeability elements in various configurations e.g., micropores, macropores, and stents/slits – designed to facilitate fluid management

OviTex PRS compared to market leading human ADM³:

- Exhibited earlier host cell proliferation, collagen deposition and neovascularization
- Demonstrated tissue remodeling into mature, functional and organized collagen

1. Certain configurations available in two or three layers, see product catalog more information. 2. Lun S, Irvine S.M., Johnson K.D., Fisher N.J., Floden E. W., Negron L., Dempsey S.G. , McLaughlin R.J., Vasudevamunthy M., Ward B.R., May B.C., A functional extracellular matrix biomaterial derived from ovine forestomach, Biomaterials 31(16) (2010) 4517-29. 3. ADM: Acellular Dermal Matrix. Overbeck N, Beierschmitt A, May B.C. (15, Koch J, In-Vivo Evaluation of a Reinforced Ovine Biologic for Plastic and Reconstructive Procedures in a Non-human Primate Model of Soft Tissue Repair. Eplasty. 2022 Sep 14;22:e43. PMID: 36160663; PMCID: PMC9490877. Animal testing results may not be indicative of clinical performance.





LIQUIFIX FIX8[™] and LIQUIFIX Precision[™]



LIQUIFIX FIX8 is intended for use in laparoscopic surgical repair of groin (femoral and inguinal) hernias, achieved through the fixation of prosthetic polypropylene or polyester mesh to the abdominal wall and the approximation of the peritoneum; LIQUIFIX Precision is intended for use in open surgical repair of groin (inguinal and femoral) hernias, achieved through the fixation of prosthetic polypropylene or polyester mesh to the abdominal wall.

Atraumatic liquid fixation devices


- Reduce the need for penetrating mechanical fixation for inguinal and femoral hernia repair
- · Provide precise, controlled adhesive application

Fills an unmet need in the market, less damage to tissue


- Designed to minimize the risk of mechanical tissue trauma¹
- Strong and secure mesh fixation^{2,3}
- · Pre-assembled device
- Adhesives polymerize in ~10 seconds
- · Provides versatile liquid anchors at multiple angles

1-3. Data on file: Advanced Medical Solutions

Driving Revenue Growth



Delivering Revenue Growth and Margin Improvement



Q1 2024 Performance

- Revenue of \$16.6M grows 39% over corresponding period of 2023
- 68% Gross Margin
 - Cash and Cash Equivalents at March 31, 2024: \$37.1M



CLINICAL REFERENCES

- 1. Sawyer, M.A.J. New Ovine Polymer-Reinforced Bioscaffold in Hiatal Hernia Repair. Jsls J Soc Laparoendosc Surg 2018, 22, e2018.00057, doi:10.4293/jsls.2018.00057.
- 2. DeNoto, G. Bridged Repair of Large Ventral Hernia Defects Using an Ovine Reinforced Biologic: A Case Series. Ann Medicine Surg 75, 103446, doi:10.1016/j.amsu.2022.103446.
- 3. Ferzoco, S. Available and Emerging Technologies for Assessing Intraoperative Tissue Perfusion during Complex Ventral Hernia Repair Procedures. Open Access Surg 2013, 1, doi:10.2147/oas.s55335.
- Ankney, C.; Banaschak, C.; Sowers, B.; Szotek, P. Minimizing Retained Foreign Body in Hernia Repair Using a Novel Technique: Reinforced Biologic Augmented Repair (ReBAR). J Clin Medical Res 2021, doi:10.37191/mapsci-2582-4333-3(4)-073.
- Sivaraj, D.; Henn, D.; Fischer, K.S.; Kim, T.S.; Black, C.K.; Lin, J.Q.; Barrera, J.A.; Leeolou, M.C.; Makarewicz, N.S.; Chen, K.; et al. Reinforced Biologic Mesh Reduces Postoperative Complications Compared to Biologic Mesh after Ventral Hernia Repair. Plastic Reconstr Surg - Global Open 2022, 10, e4083, doi:10.1097/gox.00000000004083.
- Sivaraj, D.; Henn, D.; Fischer, K.S.; Kim, T.S.; Black, C.K.; Lin, J.Q.; Barrera, J.A.; Leeolou, M.C.; Makarewicz, N.S.; Chen, K.; et al. Reinforced Biologic Mesh Reduces Postoperative Complications Compared to Biologic Mesh after Ventral Hernia Repair. Plastic Reconstr Surg - Global Open 2022, 10, e4083, doi:10.1097/gox.00000000004083.
- DeNoto, G.; Ceppa, E.P.; Pacella, S.J.; Sawyer, M.; Slayden, G.; Takata, M.; Tuma, G.; Yunis, J. 24-Month Results of the BRAVO Study: A Prospective, Multi-Center Study Evaluating the Clinical Outcomes of a Ventral Hernia Cohort Treated with OviTex® 1S Permanent Reinforced Tissue Matrix. Ann Medicine Surg 2022, 83, 104745, doi:10.1016/j.amsu.2022.104745.
- Parker, M.J.; Kim, R.C.; Barrio, M.; Socas, J.; Reed, L.R.; Nakeeb, A.; House, M.G.; Ceppa, E.P. A Novel Biosynthetic Scaffold Mesh Reinforcement Affords the Lowest Hernia Recurrence in the Highest-Risk Patients. Surg Endosc 2021, 35, 5173–5178, doi:10.1007/s00464-020-08009-1.
- 9. Banaschak, C.; Szotek, P. Robotic Reinforced Biologic Augmented Repair (ReBAR) of Over 150 Inguinal Hernias: 2 Year Outcomes. Presented at: 2022 American Hernia Society (AHS) Meeting, September 14-16, 2022, Charlotte, NC.
- Harris, H.W.; Primus, F.; Young, C.; Carter, J.T.; Lin, M.; Mukhtar, R.A.; Yeh, B.; Allen, I.E.; Freise, C.; Kim, E.; et al. Preventing Recurrence in Clean and Contaminated Hernias Using Biologic Versus Synthetic Mesh in Ventral Hernia Repair: The PRICE Randomized Clinical Trial. Ann Surg 2021, 273, 648–655, doi:10.1097/sla.00000000004336.
- Roth, J.S.; Anthone, G.J.; Selzer, D.J.; Poulose, B.K.; Pierce, R.A.; Bittner, J.G.; Hope, W.W.; Dunn, R.M.; Martindale, R.G.; Goldblatt, M.I.; et al. Prospective, Multicenter Study of P4HB (PhasixTM) Mesh for Hernia Repair in Cohort at Risk for Complications: 3-Year Follow-Up. Ann Medicine Surg 2021, 61, 1–7, doi:10.1016/j.amsu.2020.12.002.
- Hope, W.W.; El-Ghazzawy, A.G.; Winterstein, B.A.; Blatnik, J.A.; Davis, S.S.; Greenberg, J.A.; Sanchez, N.C.; Pauli, E.M.; Tseng, D.M.; LeBlanc, K.A.; et al. A Prospective, Multicenter Trial of a Long-Term Bioabsorbable Mesh with Sepra Technology in Cohort of Challenging Laparoscopic Ventral or Incisional Hernia Repairs (ATLAS Trial). Ann Medicine Surg 2022, 73, 103156, doi:10.1016/j.amsu.2021.103156.

